McKesson Corporation
MCK
$1012.34
-0.31%
McKesson Corporation is one of the three dominant U.S. pharmaceutical wholesalers, sourcing and distributing branded, generic, and specialty drugs to retail chains, independent pharmacies, hospitals, and healthcare providers, while also operating a Canadian distribution business, a medical-surgical supply unit, and pharmacy technology and oncology/multispecialty platforms. Alongside Cencora and Cardinal Health, McKesson forms an oligopoly that controls over 90% of the U.S. pharmaceutical wholesale market, giving it formidable scale, distribution density, and negotiating leverage that smaller competitors cannot replicate. The current investor narrative centers on the durability of that distribution moat combined with margin expansion in higher-value specialty and oncology services, reinforced by the company's recent agreement with CD&R to acquire Option Care Health at $32.05 per share — a deal that signals a strategic push into home and alternate-site infusion care. Management's raised guidance following strong fiscal Q1 2027 results, aggressive share repurchases, and steady execution have kept the stock in favor, though debate persists over how much of the low-margin, high-volume distribution model can be re-rated before valuation becomes stretched.…
MCK
McKesson Corporation
$1012.34
Related headlines
MCK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on McKesson Corporation's 12-month outlook, with a consensus price target around $1009.64 and implied upside of -0.3% versus the current price.
Average Target
$1009.64
0 analysts
Implied Upside
-0.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$845 - $1200
Analyst target range
Bulls vs Bears: MCK Investment Factors
The bull case rests on a durable oligopoly moat, accelerating 7.72% revenue growth, margin expansion from 3.35% to 3.50% gross, $6.19B of TTM free cash flow and a strategic push into alternate-site infusion via Option Care. The bear case is primarily valuation-driven: at 22.45x trailing and 19.87x forward earnings, near the 52-week high of $1,014.99, the average analyst target of $1,001.43 offers no upside, and the 3.61% gross margin leaves minimal room for error. On balance, the evidence favors the bulls on fundamentals but the bears on near-term risk/reward — the stock has already priced in much of the good news. The single most important tension is whether specialty and oncology mix shift can sustainably lift operating margins above 1.6%, because that is the only lever capable of justifying a further re-rating from here.
Bullish
- Oligopoly moat with 90%+ share: McKesson, Cencora and Cardinal Health control over 90% of the U.S. pharmaceutical wholesale market, a structural barrier that no new entrant can economically replicate. This scale underpins a $560.3B consensus revenue estimate for the forward year and gives MCK pricing and purchasing leverage across branded, generic and specialty categories.
- Revenue growth accelerating with margin lift: Fiscal Q1 2027 revenue of $105.38B grew 7.72% year over year from $97.83B, while gross margin expanded to 3.50% from 3.35% a year earlier. Operating income rose to $1.319B from $1.036B, a 27% increase, showing that the low-margin distribution base is being leveraged into higher-margin specialty and oncology services.
- Strong momentum and relative strength: MCK is up 29.58% over one year versus SPY's 15.53%, and 13.25% over the past month versus SPY's 1.22% — a 12.03-point relative strength spread. The stock closed at $1,004.84, near its 52-week high of $1,014.99, and has gained 22.03% year to date.
- Robust free cash flow and buybacks: TTM free cash flow is $6.185B against a $106.96B market cap, and the payout ratio is only 8.0%, leaving ample room for the aggressive share repurchases management has been executing. Diluted shares fell to 119.2M in Q1 FY2027 from 125.5M a year earlier, mechanically supporting EPS growth.
Bearish
- Razor-thin margins leave little cushion: Gross margin is just 3.61% and operating margin 1.60%, with net margin at 1.18%. At these levels, a small shift in generic drug deflation, reimbursement rates or customer mix can swing earnings disproportionately — Q1 FY2027 net income of $614M on $105.38B of revenue illustrates how little error tolerance exists.
- Valuation now at the top of its range: At $1,004.84, MCK trades at 22.45x trailing earnings and 19.87x forward earnings, with a PEG of 0.457 and EV/EBITDA of 15.55x. The stock sits within 1% of its 52-week high of $1,014.99, and the analyst average target of $1,001.43 implies essentially zero upside from here.
- Analyst consensus offers no upside: The average target price of $1,001.43 is below the current $1,004.84, and the low target of $845.00 implies roughly 16% downside. With a recommendation mean of 1.5625 (buy) but a Zacks Rank #3 cited in recent coverage, the sell-side is constructive but sees limited near-term room.
- Negative book equity and weak balance sheet optics: ROE is -219.2% and debt-to-equity is -3.97 due to negative shareholders' equity, while the current ratio of 0.854 is below 1.0. This reflects heavy buyback-driven capital return rather than distress, but it reduces financial flexibility if the Option Care integration or a downturn requires new capital.
MCK Technical Analysis
Beta
0.30
0.30x market volatility
Max Drawdown
-27.2%
Largest decline past year
52-Week Range
$724-$1030
Price range past year
Annual Return
+27.2%
Cumulative gain past year
| Period | MCK Return | S&P 500 |
|---|---|---|
| 1m | +13.6% | -1.2% |
| 3m | +20.4% | +3.4% |
| 6m | +22.2% | +7.0% |
| 1y | +27.2% | +14.4% |
| ytd | +22.9% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MCK Fundamental Analysis
Quarterly Revenue
$105.4B
2026-06
Revenue YoY Growth
+7.7%
YoY Comparison
Gross Margin
3.5%
Latest Quarter
Free Cash Flow
$6.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MCK Overvalued?
PE
22.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the extreme thinness of the margin structure. Gross margin is 3.61%, operating margin 1.60% and net margin 1.18%, meaning a 10-basis-point deterioration in gross margin on $105.38B of quarterly revenue would erase roughly $105M of gross profit — a meaningful share of the $614M quarterly net income. The current ratio of 0.854 and negative shareholders' equity (ROE of -219.2%, debt-to-equity of -3.97) reflect a buyback-heavy capital structure that leaves limited balance-sheet cushion, and the Option Care acquisition at $32.05 per share adds integration and funding risk. Revenue is also highly concentrated in U.S. pharmaceutical distribution, exposing results to generic drug deflation and customer concentration among large retail pharmacy chains.
Market and competitive risks are dominated by valuation compression. At 22.45x trailing and 19.87x forward earnings with EV/EBITDA of 15.55x, MCK trades at the upper end of its historical range and within 1% of its 52-week high of $1,014.99; any multiple normalization toward the mid-teens would imply substantial downside. The beta of 0.298 means MCK is largely insulated from broad market swings, but that low beta also means it will not benefit disproportionately from a risk-on rally, and sector rotation out of defensive healthcare distributors is a real threat. Recent news highlights that Cencora raised its FY2026 EPS outlook on specialty strength and Cardinal Health expects 8-11% pharma segment profit growth, so competitive execution risk is rising even as MCK's own Zacks Rank sits at #3.
In a worst-case scenario, generic drug deflation accelerates, specialty margin gains stall, and the Option Care integration distracts management while the stock's premium multiple compresses. The 52-week low of $723.68 represents roughly 28% downside from the current $1,004.84, and the analyst low target of $845.00 implies about 16% downside. The historical max drawdown of -27.17% is consistent with a realistic adverse outcome of a 16-28% decline, translating to a loss of roughly $160 to $281 per share from current levels if the bear case fully plays out.